Starks Associates Inc.

Starks Associates Inc. is a for-profit subchapter S corporation registered to receive federal contract awards since March 2002. The company specializes in providing preclinical services for HIV therapeutics research to the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH). Starks Associates primarily conducts synthesis and acquisition of compounds for subsequent biological in vitro and in vivo testing in support of HIV drug development efforts. Based in Buffalo, New York, the company has been awarded multiple delivery orders under a long-term indefinite-delivery/indefinite-quantity (IDIQ) contract with NIAID.

Through its federal contract awards, Starks Associates has consistently provided specialized preclinical research services focused on HIV therapeutics. The company's work involves synthesizing and acquiring batches of compounds for biological testing, developing quality assurance and quality control plans, and participating in task order initiation meetings. These services support NIAID's ongoing efforts in HIV drug discovery and development. Starks Associates has received several delivery orders from NIAID, with individual task order values ranging from approximately $1.18 million to $1.26 million annually. The work is typically performed on a cost-plus-fixed-fee basis at the company's facilities in Buffalo. Notably, these contract awards do not carry any small business or other set-aside designations.

Starks Associates holds a significant IDIQ contract with NIAID for Preclinical Services for HIV Therapeutics. This multiple-award contract, awarded in October 2020, has a ceiling value of $107,274,471 and extends through October 2027. Under this IDIQ, Starks Associates provides a wide range of preclinical development support for candidate products and drug development activities. The scope encompasses services from initial product discovery through clinical trial support, including synthesis of therapeutic agents, small animal testing, formulation development, and preclinical pharmacology and toxicology services. While primarily focused on HIV research, the contract allows flexibility to support other infectious disease priorities such as hepatitis and tuberculosis. This IDIQ serves as the parent vehicle for the numerous delivery orders awarded to Starks Associates, enabling NIAID to efficiently access the company's specialized preclinical research capabilities over an extended period.